BCI-215 is a Tumor Cell-Selective DUSP-MKP Inhibitor
Mitogen-activated protein kinase phosphatases (MKPs) belongs to the dual-specificity phosphatase (DUSP) family. DUSP-MKPs dephosphorylate and inactivate the MAPKs extracellular signal-regulated kinase (ERK), JNK/SAPK, and p38 on tyrosine and threonine residues. As a result, they result in regulating the duration and amplitude of mitogenic and survival signaling. There exists a ...
SPP-86 is a Potent and Selective Inhibitor of RET Tyrosine Kinase
The REarranged during Transfection (RET) receptor tyrosine kinase (RTK) regulates key aspects of cellular proliferation and survival by regulating the activity of the mitogen- activated protein kinase (MAPK) and PI3K/Akt signaling pathways. The RET tyrosine kinase receptor has emerged as a target in thyroid and endocrine resistant breast cancer....
Ralimetinib is a Selective and Oral Active p38 MAPK Inhibitor with Antitumor Activity
Nowadays, cancer has become no stranger to people. We mentioned it many times in our blogs. p38 MAPK (p38 mitogen-activated protein kinase) are a group of kinases responsive to stress stimuli. Once p38 MAPK activation occurs in muscle stem cells, it enhances muscle regeneration. There are four members of...